Inhibitors of Leucine Rich Repeat Kinase 2 (LRRK2) Protect Against LRRK2-Models of Parkinson’s Disease

[1]  L. Cantley,et al.  Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. , 2009, The Biochemical journal.

[2]  T. Gasser.  Molecular pathogenesis of Parkinson disease: insights from genetic studies , 2009, Expert Reviews in Molecular Medicine.

[3]  S. Riddle,et al.  Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity. , 2009, Biochemical and biophysical research communications.

[4]  B. Giasson,et al.  Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. , 2009, Biochemical and biophysical research communications.

[5]  E. Brown,et al.  Investigation of leucine‐rich repeat kinase 2 , 2009, The FEBS journal.

[6]  R. Takahashi,et al.  Phosphorylation of 4E‐BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila , 2008, The EMBO journal.

[7]  Yizheng Wang,et al.  Inhibition of glycogen synthase kinase-3β protects dopaminergic neurons from MPTP toxicity , 2007, Neuropharmacology.

[8]  K. Lim,et al.  Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. , 2007, Human molecular genetics.

[9]  C. Ross,et al.  Kinase activity of mutant LRRK2 mediates neuronal toxicity , 2006, Nature Neuroscience.

[10]  David W. Miller,et al.  Kinase activity is required for the toxic effects of mutant LRRK2/dardarin , 2006, Neurobiology of Disease.

[11]  Matthew J. Farrer,et al.  LRRK2 in Parkinson's disease: protein domains and functional insights , 2006, Trends in Neurosciences.

[12]  Andrew B West,et al.  Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[13]  刘金明,et al.  IL-13受体α2降低血吸虫病肉芽肿的炎症反应并延长宿主存活时间[英]/Mentink-Kane MM,Cheever AW，Thompson RW，et al//Proc Natl Acad Sci U S A , 2005 .

[14]  P. C. Chin,et al.  The c‐Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK‐ERK and Akt‐independent mechanism , 2004, Journal of neurochemistry.

[15]  G L Snyder,et al.  Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? , 2001, The Journal of biological chemistry.

[16]  Burton S. Rosner,et al.  Neuropharmacology , 1958, Nature.

[17]  M. Farrer,et al.  Clinical and pathologic features of families with LRRK2-associated Parkinson's disease. , 2006, Journal of neural transmission. Supplementum.